Skip to content
The Nexus
DossierENTITY

Camzyos

Coverage of Camzyos in the Nexus archive.

Earliest in view: Jul 30 · 12:20 UTCMost recent: Aug 2 · 21:27 UTC
Co-mentioned in this coverage
Bristol Myers Squibborganization2Eliquistopic2AstraZenecaorganization1Opdivotopic1Breyanzitopic1Opdualagtopic1Reblozyltopic1blood thinnertopic1
Recent coverage
  • BUSINESSAug 2 · 21:27 UTCFORTUNE
    AstraZeneca said to have explored Bristol Myers merger

    AstraZeneca Plc explored an acquisition of Bristol Myers Squibb Co., which could create one of the world's largest drugmakers. Bristol Myers Squibb, with a $133 billion market capitalization, faces patent losses for key drugs like Eliquis and Opdivo, while AstraZeneca has a market value of about £196 billion. Bristol recently reported record quarterly sales of $13 billion driven by newer treatments.

  • BUSINESSJul 30 · 12:20 UTCQUARTZ
    Bristol Myers Squibb is raising its full-year outlook after blood thinner sales surged past expectations

    Bristol Myers Squibb is raising its full-year outlook after blood thinner sales exceeded expectations. Strong sales of Eliquis, Camzyos, and Reblozyl pushed second-quarter revenue to $12.97 billion, surpassing analyst estimates.